Skip to main content
OpenTrials

Clinical trial condition

Genital Neoplasms, Female

Explore clinical trials studying Genital Neoplasms, Female. Study availability and eligibility vary by location and protocol.

4,668 public trials 1,054 recruiting studies
Refine in advanced search Browse all conditions

Genital Neoplasms, Female trial results

Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
Locations
  • University of Alabama_6th Ave Birmingham, Alabama, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber / Harvard Cancer Center Boston, Massachusetts, United States
  • Mayo Clinic - Rochester Rochester, Minnesota, United States
View all 54 locations
View Trial Details
Recruiting

Evaluation of XYA02 in Patients With Advanced Solid Tumors

NCT07670312

Conditions
Adnexal Diseases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +38 more
Locations
  • Chris O'Brien Life House Sydney, New South Wales, Australia
  • Westmead Hospital Sydney, New South Wales, Australia
  • Monash Medical Centre Melbourne, Victoria, Australia
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
View Trial Details
Recruiting

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

NCT07270666

Conditions
Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +10 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activites) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) Commack, New York, United States
View Trial Details
Recruiting

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074

Conditions
Advanced Endometrial Carcinoma, Endometrial Neoplasms, Female Urogenital Diseases, +11 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Highlands Oncology Group - Fayetteville Fayetteville, Arkansas, United States
View all 294 locations
View Trial Details
Recruiting

DESTINY-PANTUMOUR04

NCT07124000

Conditions
Adenocarcinoma, Adenocarcinoma (NOS), Adnexal Diseases, +116 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Bullhead City, Arizona, United States
  • Research Site Casa Grande, Arizona, United States
  • Research Site San Diego, California, United States
View all 18 locations
View Trial Details
Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225

Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 414 locations
View Trial Details
Recruiting

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06218914

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +32 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Newport Beach, California, United States
  • Research Site Jacksonville, Florida, United States
View all 18 locations
View Trial Details
Recruiting

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

NCT06952660

Conditions
Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +11 more
Locations
  • HonorHealth Cancer Care - Biltmore - AZCCC Imaging Phoenix, Arizona, United States
  • HonorHealth Cancer Care - Biltmore - HonorHealth Research Pharmacy Phoenix, Arizona, United States
  • HonorHealth Research Institute (Arizona Center for Cancer Care) - HonorHealth Cancer Care -Biltmore Phoenix, Arizona, United States
  • Sonora Quest Laboratories, LLC Phoenix, Arizona, United States
View all 132 locations
View Trial Details
Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703

Conditions
Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Florida Cancer Specialists - South ( Site 7001) Fort Myers, Florida, United States
  • Mount Sinai Comprehensive Cancer Center ( Site 6000) Miami Beach, Florida, United States
  • Florida Cancer Specialists - East ( Site 7000) West Palm Beach, Florida, United States
  • Winship Cancer Institute of Emory University ( Site 5005) Atlanta, Georgia, United States
View all 177 locations
View Trial Details

Related conditions